SemBioSys cuts jobs, plans company sale or shutdown

Canadian biotech company SemBioSys Genetics is exploring its strategic alternatives, including a corporate sale or merger, a strategic transaction for either insulin or Apo, an asset sale, a significant restructuring and recapitalization or a wind down of the company's operations. According to a release, the company has already laid off an unspecified number of employees. SemBioSys has been using patented plant seed, oil body and expression technology platforms to develop biosimilar drug candidates and proteins. SemBioSys release

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.